GlassScriptPhysician profile
Amir Naraghi
NPI 1255752101
$3,002.44
in general payments reported to CMS, 2019-2025
11 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $123 · 2021: $447 · 2022: $320 · 2023: $504 · 2024: $187 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $911.83 | 2019-2023 | Spravato, Xarelto |
| Amgen INC. | $491.19 | 2019 | |
| Abbvie INC. | $480.19 | 2021-2023 | |
| Angiodynamics, INC. | $345.29 | 2024-2025 | Alphavac, Angiovac |
| Teva Pharmaceuticals USA, INC. | $249.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $137.52 | 2020-2021 | |
| Mdd US Operations, LLC | $132.33 | 2019 | |
| Alkermes, INC. | $98.87 | 2022 | |
| Lilly USA, LLC | $76.75 | 2023 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.32 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $19.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Naraghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.